Abstract
Cancer stem cells (CSCs) or tumor-initiating cells (TICs) are a population of cells present within tumor that have increased self-renewal, chemoresistance, and aggressiveness, thereby contributing to tumor relapse. Literature shows that CSCs or TICs typically originate within the hypoxic niches of the tumor, making hypoxia one of the driving factors for generation of this population. Hypoxic stress promotes adaptation to low oxygen tension in the tissues by altering metabolic properties of the CSCs. This leads to a number of altered enzymatic activities in the CSC population that further contribute to the survival of the CSCs leading to resistance to standard therapy. Hence, understanding this altered metabolic pathways as well as targeting key nodes in these may pave the way for cancer management.
Glucose and glutamine are the major substrates utilized by cancer cells and feed into multiple biosynthetic pathways. Hence, labeling and tracking these compounds may reveal some novel metabolic pathways exploited by cancer stem cells to acquire survival advantage. In these current book chapters, we elaborately summarized the basic steps required for isolation, characterization, and metabolic labeling (13C6 glucose and 13C5 glutamine) of CSC for flux analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguilar-Gallardo C, Simon C (2013) Cells, stem cells, and cancer stem cells. Semin Reprod Med 31(1):5–13
Pattabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells–what challenges do they pose? Nat Rev Drug Discov 13(7):497–512
Brooks MD et al (2015) Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17(3):260–271
Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23(43):7274–7282
Balic A et al (2011) Stem cells as the root of pancreatic ductal adenocarcinoma. Exp Cell Res 318(6):691–704
Bhagwandin VJ et al (2016) The metastatic potential and chemoresistance of human pancreatic cancer stem cells. PLoS One 11(2):e0148807
Bhagwandin VJ, Shay JW (2009) Pancreatic cancer stem cells: fact or fiction? Biochim Biophys Acta 1792(4):248–259
Cho RW, Clarke MF (2008) Recent advances in cancer stem cells. Curr Opin Genet Dev 18(1):48–53
Banerjee S et al (2014) CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Clin Cancer Res 20(9):2388–2399
Bellizzi A et al (2013) Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol 228(2):408–415
Hong SP et al (2009) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125(10):2323–2331
Chiou SH et al (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14(13):4085–4095
Li C et al (2009) Identification of human pancreatic cancer stem cells. Methods Mol Biol 568(Journal Article):161–173
Li C et al (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218–2227.e2215
Liang D, Shi Y (2012) Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 29(2):633–639
Nomura A et al (2016) Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells. Oncotarget 7(35):56324–56337
Liu PP et al (2014) Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 21(1):124–135
Ciavardelli D et al (2014) Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis 5:e1336
Dando I et al (2015) The metabolic landscape of cancer stem cells. IUBMB Life 67(9):687–693
Emmink BL et al (2013) The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteome 91:84–96
Liao J et al (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 9(1):e84941
Palorini R et al (2014) Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J Cell Biochem 115(2):368–379
Zhou Y et al (2011) Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem 286(37):32843–32853
De Luca A et al (2015) Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 6(17):14777–14795
Vlashi E et al (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A 108(38):16062–16067
Wu D, Yotnda P (2011) Induction and testing of hypoxia in cell culture. J Vis Exp 54:2899
Winder CL et al (2011) TARDIS-based microbial metabolomics: time and relative differences in systems. Trends Microbiol 19(7):315–322
de Koning W, van Dam K (1992) A method for the determination of changes of glycolytic metabolites in yeast on a subsecond time scale using extraction at neutral pH. Anal Biochem 204(1):118–123
Villas-Boas SG et al (2005) Global metabolite analysis of yeast: evaluation of sample preparation methods. Yeast 22(14):1155–1169
Fiehn O (2002) Metabolomics–the link between genotypes and phenotypes. Plant Mol Biol 48(1–2):155–171
Villas-Boas SG, Bruheim P (2007) Cold glycerol-saline: the promising quenching solution for accurate intracellular metabolite analysis of microbial cells. Anal Biochem 370(1):87–97
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kesh, K., Banerjee, S. (2019). Labeling Cancer Stem Cells with 13C6 Glucose and 13C5 Glutamine for Metabolic Flux Analysis. In: Bhattacharya, S. (eds) Metabolomics. Methods in Molecular Biology, vol 1996. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9488-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9488-5_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9487-8
Online ISBN: 978-1-4939-9488-5
eBook Packages: Springer Protocols